SEPTIEMBRE 2025
Injuria renal aguda vinculada a enfermedad inflamatoria intestinal
Dr. Federico Yandiana, Dra. Martina Wilda, b, Dra. Lucía Facala, b.
aServicio de Nefrología, Médica Uruguaya, Montevideo, Uruguay.
bCentro de Nefrología, Hospital de Clínicas “Dr. Manuel Quintela”, Montevideo, Uruguay.
Clásicamente las MEI se clasifican en dos grandes grupos: (I) manifestaciones reactivas asociadas a la actividad inflamatoria intestinal, que comparten mecanismos patogénicos con la enfermedad intestinal como artritis, eritema nodoso, pioderma gangrenoso, estomatitis aftosa, iritis o uveítis; (II) enfermedades autoinmunes independientes de la actividad intestinal que reflejan una mayor susceptibilidad a la autoinmunidad asociada a predisposición genética, fenómenos de autorreconocimiento aberrante y autoanticuerpos órgano-específicos compartidos entre el colon y órganos extraintestinales, como espondilitis anquilosante, colangitis biliar primaria, alopecia areata y enfermedad tiroidea autoinmune5,7. Oikonomou et al. propusieron un tercer grupo: (III) manifestaciones derivadas de alteraciones metabólicas directamente relacionadas con la EII, como malabsorción, síndrome de intestino corto tras resección y sobrecrecimiento bacteriano. Asimismo, los autores plantearon que las MEI pueden relacionarse con efectos adversos de los tratamientos utilizados para controlar la inflamación intestinal.
Daño renal en enfermedad inflamatoria intestinal
En la serie retrospectiva más amplia publicada de biopsias renales nativas en pacientes con EII, realizada en la Clínica Mayo (Rochester, Minnesota) entre 1994 y 2022, se analizaron 318 casos, se siguieron 111 pacientes (45 con CU y 66 con EC), con una media de edad de 48 ± 17 años, de los cuales el 40% eran mujeres. Los diagnósticos más frecuentes fueron NIgA (22%), NTIC (19%) y NTIA (13%). Tras una mediana de seguimiento de 59 meses, 29 pacientes (26%) progresaron a ERT. En el análisis multivariable, los principales predictores de insuficiencia renal fueron la edad (HR: 1,04; p=0,002), la tasa de filtrado glomerular estiado (TFGe) basal (HR: 0,94; p=0,003) y la puntuación de cronicidad histológica (HR: 4,01; p=0,001). El manejo terapéutico varió según la etiología, siendo frecuentes los corticosteroides y otros inmunosupresores en casos seleccionados. La remisión parcial o completa de la proteinuria, así como la estabilización o mejoría de la función renal, se asociaron con una mayor supervivencia global (definida como libre de insuficiencia renal y muerte). Cabe destacar que aproximadamente una cuarta parte de los pacientes con EII y compromiso renal progresaron a ERT17.
Daño renal en enfermedad inflamatoria intestinal
Por otra parte, si el sedimento es “activo” (con hematuria y/o proteinuria significativa) debe valorarse la posibilidad de que corresponda a una glomerulopatía. La NIgA es la más prevalente y, si bien suele considerarse primaria, diversos hallazgos sugieren que, en subgrupos de pacientes, puede ser secundaria a la propia EII11,12,17,19. La mayor frecuencia de NIgA en biopsias de pacientes con EII respecto de otras series, la correlación clínica entre brotes intestinales y actividad glomerular con mejoría renal tras el control de la inflamación intestinal y la presencia de asociaciones genéticas compartidas (como HLADR1 para NIgA y HLADR1/DQw5 para EC), junto con loci de riesgo comunes identificados por estudios de asociación genómica, apoyan un vínculo fisiopatológico9,18,19,66. También se ha descrito NIgA como efecto adverso de terapias anti-TNF, particularmente adalimumab67 e infliximab9, si bien infliximab ha mostrado eficacia en casos de NIgA asociada a EC, lo que ilustra la complejidad de las relaciones causales68,69. La vasculitis por IgA es excepcional, pero ha sido comunicada en casos aislados43,70,71. La amiloidosis secundaria con compromiso renal es muy infrecuente, más prevalente en EC que representa la cuarta causa de amiloidosis secundaria y suele aparecer en el contexto de una EII extensa y refractaria, especialmente con afectación ileocólica o del intestino delgado proximal72–75.
Autores
Dr. Federico Yandiana
Dra. Martina Wilda
Dra. Lucía Facala
Cita: slanh.net/redira
CONCLUSIONES
- Vinculado a toxicidad por fármacos.
- Vinculado a una MEI activa.
- Concomitancia de una glomerulopatía en un paciente con EII.
Bibliografía
- Yang, Z., Xu, X., Dong, Y. & Zhang, Y. The pathological and outcome characteristics of renal lesions in Crohn’s disease. BMC Nephrol 23, 1–11 (2022).
- Loddo, I. & Romano, C. Inflammatory bowel disease: Genetics, epigenetics, and pathogenesis. Front Immunol 6, 6–11 (2015).
- Babickova, J. & Gardlik, R. Pathological and therapeutic interactions between bacteriophages, microbes and the host in inflammatory bowel disease. World J Gastroenterol 21, 11321–11330 (2015).
- Ng, S. C. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet 390, 2769–2778 (2017).
- Danese, S. et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 11, 7227–7236 (2005).
- Annese, V. A review of extraintestinal manifestations and complications of inflammatory bowel disease. Saudi J Med Med Sci 7, 66 (2019).
- Larsen, S., Bendtzen, K. & Nielsen, O. L. E. H. Extraintestinal manifestations of infl ammatory bowel disease: Epidemiology, diagnosis, and management. 97–114 (2010).
- van Bodegraven, A. A. & Peña, A. S. Treatment of extraintestinal manifestations in inflammatory bowel disease. Curr Treat Options Gastroenterol 6, 201–212 (2003).
- Oikonomou, K., Kapsoritakis, A., Eleftheriadis, T., Stefanidis, I. & Potamianos, S. Renal manifestations and complications of inflammatory bowel disease. Inflamm Bowel Dis 17, 1034–1045 (2011).
- Mutalib, M. Renal involvement in paediatric inflammatory bowel disease. Pediatric Nephrology 36, 279–285 (2021).
- Ambruzs, J. M. & Larsen, C. P. Renal Manifestations of Inflammatory Bowel Disease. Rheumatic Disease Clinics of North America 44, 699–714 (2018).
- Ambruzs, J. M., Walker, P. D. & Larsen, C. P. The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin J Am Soc Nephrol 9, 265–270 (2014).
- Vrus, J. & Jukić, N. B. Inflammatory Bowel Diseases in Renal Transplantat Recipients: A Case Series and Review of the Literature. Prilozi 43, 57–63 (2022).
- Dincer, M. T. et al. Renal Manifestations in Inflammatory Bowel Disease: A Cohort Study During the Biologic Era. Medical Science Monitor 28, 1–10 (2022).
- Shield, D. E., Lytton, B., Weiss, R. M. & Schiff, M. Urologic complications of inflammatory bowel disease. Journal of Urology 115, 701–706 (1976).
- Pardi, D. Renal and Urologic Complications of Inflammatory Bowel Disease. Am J Gastroenterol 93, 504–514 (1998).
- Yandian, F. et al. Kidney Diseases Associated With Inflammatory Bowel Disease: Impact of Chronic Histologic Damage, Treatments, and Outcomes. Kidney Int Rep 9, 383–394 (2024).
- Filiopoulos, V. et al. IgA nephropathy in association with Crohn’s disease: A case report and brief review of the literature. Ren Fail 32, 523–527 (2010).
- Pohjonen, J. et al. Inflammatory bowel disease in patients undergoing renal biopsies. Clin Kidney J 12, 645–651 (2019).
- Waters, A. M., Zachos, M., Herzenberg, A. M., Harvey, E. & Rosenblum, N. D. Tubulointerstitial nephritis as an extraintestinal manifestation of Crohn’s disease. Nat Clin Pract Nephrol 4, 693–697 (2008).
- Lok, K. H. et al. Fulminant ulcerative colitis associated with steroid-resistant minimal change disease and psoriasis: A case report. World J Gastroenterol 13, 4022–4024 (2007).
- Fornaciari, G. et al. Nephrotic syndrome from 5-ASA for ulcerative colitis? Complicated by carcinoma of the colon and sclerosing cholangitis. J Clin Gastroenterol 24, 37–39 (1997).
- Firwana, B. M. et al. Nephrotic syndrome after treatment of Crohn′s disease with mesalamine: Case report and literature review. Avicenna J Med 02, 9–11 (2012).
- Skhiri, H., Knebelmann, B., Martin-Lefevre, L. & Grunfeld, J. P. Nephrotic syndrome associated with inflammatory dowel disease treated by mesalazine [12]. Nephron 79, 236 (1998).
- Novis, B. H., Korzets, Z., Chen, P. & Bernheim, J. Nephrotic syndrome after treatment with 5-aminosalicylic acid. Br Med J (Clin Res Ed) 296, 1442 (1988).
- Molnár, T., Farkas, K., Nagy, F., Iványi, B. & Wittmann, T. Sulfasalazine-induced nephrotic syndrome in a patient with ulcerative colitis. Inflamm Bowel Dis 16, 552–553 (2010).
- Fofi, C., Nicoletti, M. C. D., Onetti Muda, A. & Giulio, S. [Focal segmental glomerulosclerosis with IgA deposits in a patient with ulcerative colitis]. G Ital Nefrol 20, 641–644 (2003).
- Ridder, R. M., Kreth, H. W., Kiss, E., Gröne, H. J. & Gordjani, N. Membranous nephropathy associated with familial chronic ulcerative colitis in a 12-year-old girl. Pediatric Nephrology 20, 1349–1351 (2005).
- Casella, G. et al. A rare association between ulcerative colitis (UC), celiac disease (CD), membranous glomerulonephritis, leg venous thrombosis, and heterozygosity for factor V Leiden. Journal of gastroenterology vol. 37 761–762 Preprint at https://doi.org/10.1007/s005350200126 (2002).
- Warling, O. et al. Overlap syndrome consisting of PSC-AIH with concomitant presence of a membranous glomerulonephritis and ulcerative colitis. World J Gastroenterol 20, 4811–4816 (2014).
- Molina-Pérez, M., González-Reimers, E., Santolaria-Fernández, F., Maceira-Cruz, B. & Ravina-Cabrera, M. Rapidly progressive glomerulonephritis and inflammatory bowel disease. Diseases of the colon and rectum vol. 38 1006–1007 Preprint at https://doi.org/10.1007/BF02049742 (1995).
- Wilcox, G. M., Aretz, H. T., Roy, M. A. & Roche, J. K. Glomerulonephritis associated with inflammatory bowel disease. Report of a patient with chronic ulcerative colitis, sclerosing cholangitis, and acute glomerulonephritis. Gastroenterology 98, 786–791 (1990).
- Marques Da Costa, P., Correia, L. & Correia, L. A. The Complexity of Renal Involvment in IBD – C3 Glomerulopathy in Ulcerative Colitis. Inflamm Bowel Dis 24, e4–e5 (2018).
- Ko, J. L. et al. Concomitant aseptic subcutaneous abscess and immunoglobulin M nephropathy – Rare extraintestinal manifestations in ulcerative colitis. Dig Dis Sci 51, 401–405 (2006).
- Shaer, A. J., Stewart, L. R., Cheek, D. E., Hurray, D. & Self, S. E. Selected Features of Patients With Glomerulonephritis Associated With IBD. 41, 1097–1109 (2003).
- Plaisier, E. et al. Anti-glomerular basement membrane nephritis and bullous pemphigoid caused by distinct anti-α3(IV)NC1 and anti-BP180 antibodies in a patient with Crohn’s disease. American Journal of Kidney Diseases 40, 649–654 (2002).
- Hibbs, A. M., Bznik-Cizman, B., Guttenberg, M., Goldberg, B. & Meyers, K. Ulcerative colitis in a renal transplant patient with previous goodpasture disease. Pediatric Nephrology 16, 543–546 (2001).
- Nakamura, T., Suzuki, Y. & Koide, H. Granulocyte and monocyte adsorption apheresis in a patient with antiglomerular basement membrane glomerulonephritis and active ulcerative colitis. American Journal of the Medical Sciences 325, 296–298 (2003).
- Presti, M. E., Neuschwander-Tetri, B. A., Vogler, C. A., Janney, C. G. & Roche, J. K. Sclerosing cholangitis, inflammatory bowel disease, and glomerulonephritis: a case report of a rare triad. Dig Dis Sci 42, 813–816 (1997).
- Children, S. & Road, S. Proliferative glomerulonephritis associated with Crohn ’ s disease Algorithm for modified alkaline diuresis in salicylate poisoning. Br Med J 289, 1039–1040 (1984).
- Hellwege, H. H., Bläker, F. & Gebbers, J. O. [Hypocomplementemic membranoproliferative glomerulonephritis in a child with ulcerative colitis (author’s transl)]. Monatsschr Kinderheilkd 124, 706–711 (1976).
- Moayyedi, P., Fletcher, S., Harnden, P., Axon, A. T. R. & Brownjohn, A. Mesangiocapillary glomerulonephritis associated with ulcerative colitis: Case reports of two patients. Nephrology Dialysis Transplantation 10, 1923–1924 (1995).
- Peeters, A. J., Van Den Wall Bake, A. W. L., Daha, M. R. & Breedveld, F. C. Inflammatory bowel disease and ankylosing spondylitis associated with cutaneous vasculitis, glomerulonephritis, and circulating IgA immune complexes. Ann Rheum Dis 49, 638–640 (1990).
- Gisbert, J. P., González-Lama, Y. & Maté, J. 5-Aminosalicylates and renal function in inflammatory bowel disease: A systematic review. Inflamm Bowel Dis 13, 629–638 (2007).
- De Broe, M. E., Stolear, J. C., Nouwen, E. J. & Elseviers, M. M. 5-Aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: Is there a link? Nephrology Dialysis Transplantation 12, 1839–1841 (1997).
- Corrigan, G. & Stevens, P. E. Review article: Interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 14, 1–6 (2000).
- Fraser, J. S., Muller, A. F., Smith, D. J., Newman, D. J. & Lamb, E. J. Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy. Aliment Pharmacol Ther 15, 1131–1137 (2001).
- Margetts, P. J., Churchill, D. N. & Alexopoulou, I. Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine. J Clin Gastroenterol 32, 176–178 (2001).
- Arend, L. J. & Springate, J. E. Interstitial nephritis from mesalazine: Case report and literature review. Pediatric Nephrology 19, 550–553 (2004).
- Adiga, A. & Goldfarb, D. S. The Association of Mesalamine With Kidney Disease. Adv Chronic Kidney Dis 27, 72–76 (2020).
- Gisbert, J. P. et al. Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-Year follow-up study. Gastroenterol Hepatol 31, 477–484 (2008).
- Moss, J. G., Parry, C. M., Holt, R. C. L. & McWilliam, S. J. 5-ASA induced interstitial nephritis in patients with inflammatory bowel disease: a systematic review. Eur J Med Res 27, 1–9 (2022).
- Izzedine, H. et al. Primary chronic interstitial nephritis in crohn’s disease. Gastroenterology 123, 1436–1440 (2002).
- Angeletti, A. et al. Different renal manifestations associated with very early onset pediatric inflammatory bowel disease: case report and review of literature. BMC Nephrol 22, 2–7 (2021).
- Corica, D. & Romano, C. Renal involvement in inflammatory bowel diseases. J Crohns Colitis 10, 1–10 (2015).
- Herrlinger, K. R. et al. Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. Aliment Pharmacol Ther 15, 363–369 (2001).
- Timmermans, S. A. M. E. G. et al. Granulomatous interstitial nephritis and Crohn’s disease. Clin Kidney J 9, 556–559 (2016).
- Semjén, D. et al. Renal involvement in Crohn’s disease: Granulomatous inflammation in the form of mass lesion. Eur J Gastroenterol Hepatol 23, 1267–1269 (2011).
- Joyce, E., Glasner, P., Ranganathan, S. & Swiatecka-Urban, A. Tubulointerstitial nephritis: diagnosis, treatment, and monitoring. Pediatric Nephrology 32, 577–587 (2017).
- Akiyama, M. et al. Crohn’s disease may promote inflammation in IgA nephropathy: a case–control study of patients undergoing kidney biopsy. Virchows Archiv 481, 553–563 (2022).
- Thuluvath, P. J., Ninkovic, M., Calam, J. & Anderson, M. Mesalazine induced interstitial nephritis. Gut 35, 1493–1496 (1994).
- González, E. et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int 73, 940–946 (2008).
- Vasanth, P., Parmley, M., Torrealba, J. & Hamdi, T. Interstitial Nephritis in a Patient with Inflammatory Bowel Disease. Case Rep Nephrol 2016, 1–3 (2016).
- Preddie, D. C. et al. Mycophenolate mofetil for the treatment of interstitial nephritis. Clin J Am Soc Nephrol 1, 718–722 (2006).
- Praga, M. & González, E. Acute interstitial nephritis. Kidney Int 77, 956–961 (2012).
- Kiryluk, K. et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46, 1187–1196 (2014).
- Singh, A. K. B., Jeyaruban, A. S., Wilson, G. J. & Ranganathan, D. Adalimumab-induced IgA nephropathy. BMJ Case Rep 12, 1–4 (2019).
- Bruzzese, V. et al. IgA nephropathy onset in a Crohn’s disease patient treated with Adalimumab. Minerva gastroenterologica e dietologica vol. 62 223–224 Preprint at (2016).
- Ueno, Y. et al. Infliximab treatment for Crohn’s disease in a patient with IgA nephropathy. Clin J Gastroenterol 2, 380–383 (2009).
- H.M., J. et al. Renal involvement in children and adolescents with inflammatory bowel disease. Korean J Pediatr 61, 327–331 (2018).
- Sequeira, C. et al. Henoch-Sch�nlein purpura masquerading as Crohn�s disease flare. Revista Española de Enfermedades Digestivas (2022) doi:10.17235/reed.2022.9414/2022.
- Greenstein, A. J. et al. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine 71, 261–270 (1992).
- Wester, A. L., Vatn, M. H. & Fausa, O. Secondary amyloidosis in inflammatory bowel disease: A study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis 7, 295–300 (2001).
- Cuquerella, J. T. et al. Amyloidosis in inflammatory bowel disease: A systematic review of epidemiology, clinical features, and treatment. J Crohns Colitis 10, 1245–1253 (2016).
- Motamed, F. et al. Systemic amyloidosis in a teenage boy with inflammatory bowel disease. Acta Med Iran 55, 265–267 (2017).
ARTÍCULOS SEPTIEMBRE 2025
Autoevaluación
Comité de Injuria Renal Aguda: Rolando Claure-Del Granado, Jonathan Chavez-Iñiguez, Alejandro Ferreiro, Daniela Ponce.
Consejo Editor: Dres. Raúl Lombardi, Jonathan Chávez-Iñiguez, Pablo Galindo, Ana Guerisoli, Lilia Rizo-Topete, Federico Yandian.
Secretaria: Viviana Falcone